ReviewDermatologie (Heidelberg, Germany)2026
[Therapeutic options for occupational skin cancer (BK 5102, BK 5103)].
Review in Dermatologie (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIncidence of keratinocyte skin cancer has been continuously rising in recent decades. At the same time, the number of occupational skin cancers has also increased. Treatment depends on clinical manifestation, extent of actinic keratosis, field cancerization and, in case of squamous cell carcinoma, on the tumor stage.
objectivesThis work aims to enhance the understanding of the challenges associated with the treatment of occupational skin cancer. MATERIALS AND
methodsThis article is based on a review of the literature.
resultsDifferent therapeutic options for the treatment of occupational skin cancer are presented and discussed.
conclusionThe need to treat occupational skin cancer is expected to increase in the future. An increasing number of modern therapeutic options will enable adequate patient care.
Indexed as
Identifiers
41975010What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.